Related Experiment Video

Updated: Jun 19, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

HIC1 regulates tumor cell responses to endocrine therapies

Baohua Zhang1, Douglas V Faller, Sheng Wang

  • 1Boston University School of Medicine, Cancer Research Center, Massachusetts 02118, USA.

Molecular Endocrinology (Baltimore, Md.)
|October 13, 2009
PubMed

Insights

The tumor suppressor HIC1 is crucial for estrogen antagonist effectiveness in breast cancer. Restoring HIC1 in resistant cells re-sensitizes them to endocrine therapy, offering new treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Endocrinology

Background:

  • Breast cancer endocrine therapy resistance is a major clinical challenge.
  • The tumor suppressor heavily methylated in cancers 1 (HIC1) regulates cell growth.
  • Understanding resistance mechanisms is vital for improving breast cancer treatment.

Purpose of the Study:

  • To investigate the role of HIC1 in estrogen antagonist sensitivity in breast cancer.
  • To elucidate the molecular mechanisms underlying HIC1 regulation by estrogen antagonists.
  • To explore HIC1 as a potential therapeutic target for overcoming endocrine resistance.

Main Methods:

  • Assessing HIC1 expression in tamoxifen-sensitive and resistant breast cancer cells.
  • Utilizing cell culture models to study HIC1 reintroduction in resistant cells.
  • Investigating signaling pathways, including JNK1 and prohibitin, involved in HIC1 induction.

Main Results:

  • HIC1 is required for growth suppression by estrogen antagonists in sensitive breast cancer cells.
  • Estrogen antagonists induce HIC1 expression via a JNK1 and prohibitin-mediated pathway in sensitive cells.
  • HIC1 induction is lost in spontaneously resistant breast cancer cells, but reintroduction restores sensitivity.

Conclusions:

  • HIC1 acts as a novel tumor suppressor essential for estrogen antagonist efficacy.
  • HIC1 induction by estrogen antagonists represents a key regulatory mechanism for breast cancer cell growth control.
  • Restoring HIC1 function may overcome tamoxifen resistance in breast cancer.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Concept Videos

Target Cell Response to Hormones01:22

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...